Teva Pharmaceuticals Industries Ltd., (TEVA) Tuesday said the U.S. Food and Drug Administration or FDA has accepted its supplemental new drug application or sNDA for a lower dose QNASL Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis in children 4-11 years of age. The sNDA contained data from three double-blind, placebo-controlled studies, which showed that once-daily treatment with QNASL provided significant nasal allergy symptom relief in pediatric subjects with seasonal and perennial allergic rhinitis when compared with placebo. In all three studies, the safety profile of QNASL was similar to that of placebo and adverse events were consistent with those seen in previous clinical studies. Further, the company said, if the FDA approves the new indication for QNASL, it will become the first waterless HFA nasal allergy treatment for patients as young as 4 years of age.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.